NO311807B1 - HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV - Google Patents
HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV Download PDFInfo
- Publication number
- NO311807B1 NO311807B1 NO19991078A NO991078A NO311807B1 NO 311807 B1 NO311807 B1 NO 311807B1 NO 19991078 A NO19991078 A NO 19991078A NO 991078 A NO991078 A NO 991078A NO 311807 B1 NO311807 B1 NO 311807B1
- Authority
- NO
- Norway
- Prior art keywords
- xaa
- seq
- leu
- gly
- ala
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 114
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 49
- 239000000427 antigen Substances 0.000 title claims description 33
- 108091007433 antigens Proteins 0.000 title claims description 33
- 102000036639 antigens Human genes 0.000 title claims description 33
- 229960005486 vaccine Drugs 0.000 title claims description 33
- 238000002360 preparation method Methods 0.000 title claims description 28
- 238000000034 method Methods 0.000 title claims description 8
- 238000003018 immunoassay Methods 0.000 title claims description 7
- 150000001413 amino acids Chemical group 0.000 claims description 45
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 20
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 20
- 101710147327 Calcineurin B homologous protein 1 Proteins 0.000 claims description 19
- 101710205625 Capsid protein p24 Proteins 0.000 claims description 19
- 101710177166 Phosphoprotein Proteins 0.000 claims description 19
- 101710149279 Small delta antigen Proteins 0.000 claims description 19
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 claims description 19
- 239000002671 adjuvant Substances 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 150000001408 amides Chemical class 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 7
- 239000003102 growth factor Substances 0.000 claims description 6
- 239000000470 constituent Substances 0.000 claims description 5
- 230000003308 immunostimulating effect Effects 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- IUZGUFAJDBHQQV-YUMQZZPRSA-N Gly-Leu-Asn Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IUZGUFAJDBHQQV-YUMQZZPRSA-N 0.000 claims description 2
- WGNOPSQMIQERPK-UHFFFAOYSA-N Leu-Asn-Pro Natural products CC(C)CC(N)C(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)O WGNOPSQMIQERPK-UHFFFAOYSA-N 0.000 claims description 2
- FKVNLUZHSFCNGY-RVMXOQNASA-N Pro-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 FKVNLUZHSFCNGY-RVMXOQNASA-N 0.000 claims description 2
- SUENWIFTSTWUKD-AVGNSLFASA-N Pro-Leu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O SUENWIFTSTWUKD-AVGNSLFASA-N 0.000 claims description 2
- IWAVRIPRTCJAQO-HSHDSVGOSA-N Thr-Pro-Trp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O IWAVRIPRTCJAQO-HSHDSVGOSA-N 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 32
- 238000004128 high performance liquid chromatography Methods 0.000 description 25
- 208000031886 HIV Infections Diseases 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 238000004989 laser desorption mass spectroscopy Methods 0.000 description 13
- 238000004949 mass spectrometry Methods 0.000 description 13
- 208000030507 AIDS Diseases 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 239000007858 starting material Substances 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 11
- 238000011161 development Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 6
- 239000006249 magnetic particle Substances 0.000 description 6
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 238000010183 spectrum analysis Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229940021993 prophylactic vaccine Drugs 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229940021747 therapeutic vaccine Drugs 0.000 description 3
- 229940125575 vaccine candidate Drugs 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- OIOAKXPMBIZAHL-LURJTMIESA-N (2s)-2-azaniumyl-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoate Chemical compound CC(C)(C)OC(=O)CC[C@H](N)C(O)=O OIOAKXPMBIZAHL-LURJTMIESA-N 0.000 description 1
- ANAZDOWEOOFEET-UHFFFAOYSA-N (4-hydroxyphenyl) [4-(3-oxo-1h-2-benzofuran-1-yl)phenyl] hydrogen phosphate Chemical compound C1=CC(O)=CC=C1OP(O)(=O)OC1=CC=C(C2C3=CC=CC=C3C(=O)O2)C=C1 ANAZDOWEOOFEET-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-UHFFFAOYSA-N 2-aminohexanoic acid Chemical compound CCCCC(N)C(O)=O LRQKBLKVPFOOQJ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 108700020403 Human Immunodeficiency Virus Type 1 p24 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- BCVIOZZGJNOEQS-XKNYDFJKSA-N Ile-Ile Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)[C@@H](C)CC BCVIOZZGJNOEQS-XKNYDFJKSA-N 0.000 description 1
- 102100034353 Integrase Human genes 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011850 initial investigation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
Priority Applications (36)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO19991078A NO311807B1 (no) | 1999-03-04 | 1999-03-04 | HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV |
| NZ514619A NZ514619A (en) | 1999-03-04 | 2000-03-02 | HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV |
| AT00911492T ATE397014T1 (de) | 1999-03-04 | 2000-03-02 | Hiv-peptide, antigene und impfstoffzusammensetzungen |
| DK00911492T DK1159298T3 (da) | 1999-03-04 | 2000-03-02 | HIV-peptider, antigener og vaccinekompositioner |
| IDW00200102137A ID30497A (id) | 1999-03-04 | 2000-03-02 | Peptida hiv, antigen, komposisi vaksin, kit imunoasai dan metoda untuk mendeteksi antibodi yang diinduksi oleh hiv |
| PT00911492T PT1159298E (pt) | 1999-03-04 | 2000-03-02 | Péptidos de hiv, antigénios, composições de vacinas, kit de imunoensaio e um método de detecção de anticorpos induzidos por hiv |
| SK1240-2001A SK287382B6 (sk) | 1999-03-04 | 2000-03-02 | Očkovacia kompozícia |
| NZ525753A NZ525753A (en) | 1999-03-04 | 2000-03-02 | HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV |
| AU33358/00A AU771827B2 (en) | 1999-03-04 | 2000-03-02 | HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV |
| ES00911492T ES2307496T4 (es) | 1999-03-04 | 2000-03-02 | Composiciones de vacuna, antígenos y péptidos de VIH |
| CA002363947A CA2363947C (en) | 1999-03-04 | 2000-03-02 | Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv |
| CNB008057354A CN100387617C (zh) | 1999-03-04 | 2000-03-02 | Hiv肽,抗原,疫苗组合物,检测hiv所诱导的抗体的免疫测定试剂盒及方法 |
| CZ20013195A CZ300505B6 (cs) | 1999-03-04 | 2000-03-02 | Vakcinacní prípravek |
| CNA2008100921311A CN101328209A (zh) | 1999-03-04 | 2000-03-02 | Hiv肽，抗原，疫苗组合物，检测hiv所诱导的抗体的免疫测定试剂盒及方法 |
| NZ525751A NZ525751A (en) | 1999-03-04 | 2000-03-02 | HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV |
| HU0200265A HU229282B1 (en) | 1999-03-04 | 2000-03-02 | Hiv vaccine compositions |
| EP00911492A EP1159298B1 (en) | 1999-03-04 | 2000-03-02 | Hiv peptides, antigens and vaccine compositions |
| DE60039036T DE60039036D1 (de) | 1999-03-04 | 2000-03-02 | Hiv-peptide, antigene und impfstoffzusammensetzungen |
| US09/674,674 US6706859B1 (en) | 1999-03-04 | 2000-03-02 | HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV |
| CNA2008100921326A CN101328210A (zh) | 1999-03-04 | 2000-03-02 | Hiv肽，抗原，疫苗组合物，检测hiv所诱导的抗体的免疫测定试剂盒及方法 |
| BR0008741-6A BR0008741A (pt) | 1999-03-04 | 2000-03-02 | Peptìdeo de hiv, antìgenos, composições de vacina, kit de imunoensaio e método de detecção de anticorpos induzidos por hiv |
| JP2000602264A JP2002541069A (ja) | 1999-03-04 | 2000-03-02 | Ｈｉｖペプチド、抗原、ワクチン組成物、免疫学的検定キット及びｈｉｖによって誘発された抗体を検出する方法 |
| PCT/NO2000/000075 WO2000052040A1 (en) | 1999-03-04 | 2000-03-02 | Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv |
| EA200100943A EA004802B9 (ru) | 1999-03-04 | 2000-03-02 | МОДИФИЦИРОВАННЫЕ ВИЧ-ПЕПТИДЫ НА ОСНОВЕ БЕЛКА gag p24, АНТИГЕНЫ, ВАКЦИННЫЕ КОМПОЗИЦИИ, НАБОР ДЛЯ ИММУНОАНАЛИЗА И СПОСОБ ОПРЕДЕЛЕНИЯ ВИЧ-ИНДУЦИРОВАННЫХ АНТИТЕЛ |
| NZ525752A NZ525752A (en) | 1999-03-04 | 2000-03-02 | HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV |
| CNA2008100921330A CN101328208A (zh) | 1999-03-04 | 2000-03-02 | Hiv肽，抗原，疫苗组合物，检测hiv所诱导的抗体的免疫测定试剂盒及方法 |
| ZA200107072A ZA200107072B (en) | 1999-03-04 | 2001-08-27 | HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV. |
| HK02106292.0A HK1044778B (zh) | 1999-03-04 | 2002-08-27 | Hiv肽，抗原，疫苗組合物，檢測hiv所誘導的抗體的免疫測定試劑盒及方法 |
| US10/659,324 US7311915B2 (en) | 1999-03-04 | 2003-09-11 | Method of producing an HIV-1 immune response |
| US11/865,109 US7709004B2 (en) | 1999-03-04 | 2007-10-01 | Method of producing an HIV-1 immune response |
| US11/865,106 US7709003B2 (en) | 1999-03-04 | 2007-10-01 | Method of producing an HIV-1 immune response |
| CY20081100922T CY1108299T1 (el) | 1999-03-04 | 2008-08-28 | Πεπτιδια του ιου ανθρωπινης ανοσοανεπαρκειας (hiv), αντιγονα και συνθεσεις εμβολιου |
| JP2010275025A JP5313998B2 (ja) | 1999-03-04 | 2010-12-09 | Ｈｉｖペプチド、抗原、ワクチン組成物、免疫学的検定キット及びｈｉｖによって誘発された抗体を検出する方法 |
| JP2012239940A JP5695010B2 (ja) | 1999-03-04 | 2012-10-31 | Ｈｉｖペプチド、抗原、ワクチン組成物、免疫学的検定キット及びｈｉｖによって誘発された抗体を検出する方法 |
| JP2012240131A JP5695012B2 (ja) | 1999-03-04 | 2012-10-31 | Ｈｉｖペプチド、抗原、ワクチン組成物、免疫学的検定キット及びｈｉｖによって誘発された抗体を検出する方法 |
| JP2013249096A JP5814331B2 (ja) | 1999-03-04 | 2013-12-02 | Ｈｉｖペプチド、抗原、ワクチン組成物、免疫学的検定キット及びｈｉｖによって誘発された抗体を検出する方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO19991078A NO311807B1 (no) | 1999-03-04 | 1999-03-04 | HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO991078D0 NO991078D0 (no) | 1999-03-04 |
| NO991078L NO991078L (no) | 2000-09-05 |
| NO311807B1 true NO311807B1 (no) | 2002-01-28 |
Family
ID=19903050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19991078A NO311807B1 (no) | 1999-03-04 | 1999-03-04 | HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US6706859B1 (zh) |
| EP (1) | EP1159298B1 (zh) |
| JP (5) | JP2002541069A (zh) |
| CN (4) | CN101328208A (zh) |
| AT (1) | ATE397014T1 (zh) |
| AU (1) | AU771827B2 (zh) |
| BR (1) | BR0008741A (zh) |
| CA (1) | CA2363947C (zh) |
| CY (1) | CY1108299T1 (zh) |
| CZ (1) | CZ300505B6 (zh) |
| DE (1) | DE60039036D1 (zh) |
| DK (1) | DK1159298T3 (zh) |
| EA (1) | EA004802B9 (zh) |
| ES (1) | ES2307496T4 (zh) |
| HK (1) | HK1044778B (zh) |
| HU (1) | HU229282B1 (zh) |
| ID (1) | ID30497A (zh) |
| NO (1) | NO311807B1 (zh) |
| NZ (4) | NZ525752A (zh) |
| PT (1) | PT1159298E (zh) |
| SK (1) | SK287382B6 (zh) |
| WO (1) | WO2000052040A1 (zh) |
| ZA (1) | ZA200107072B (zh) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1307130A4 (en) | 2000-02-04 | 2005-01-12 | Beth Israel Hospital | VACCINE AGAINST HUMAN IMMUNE WEAK VIRUS |
| NO314588B1 (no) * | 2000-09-04 | 2003-04-14 | Bionor Immuno As | HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV |
| NO314587B1 (no) * | 2000-09-04 | 2003-04-14 | Bionor Immuno As | HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV |
| CN102443052B (zh) | 2006-03-10 | 2014-12-31 | 派特塞尔有限公司 | Hiv的调节或辅助蛋白的肽、组合物及它们的应用 |
| JP5775451B2 (ja) | 2008-06-19 | 2015-09-09 | バリエーション バイオテクノロジーズ インコーポレイティド | インフルエンザを処置するための組成物および方法 |
| WO2011005772A1 (en) | 2009-07-06 | 2011-01-13 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| CN102482666B (zh) | 2009-07-06 | 2017-02-08 | 变异生物技术公司 | 制备囊泡的方法和由其产生的制剂 |
| EP3187585A1 (en) | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
| WO2012006367A2 (en) | 2010-07-06 | 2012-01-12 | Variation Biotechnologies, Inc. | Compositions and methods for treating influenza |
| EP2646459B1 (en) * | 2010-12-02 | 2020-01-08 | Bionor Immuno AS | Peptide scaffold design |
| CN103501811B (zh) | 2011-01-13 | 2016-03-30 | 变异生物技术公司 | 用于治疗病毒感染的组合物和方法 |
| DK2691530T3 (en) | 2011-06-10 | 2018-05-22 | Univ Oregon Health & Science | CMV GLYCOPROTEIN AND RECOMBINANT VECTORS |
| EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
| CA2894442C (en) | 2012-01-12 | 2020-01-21 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
| RU2698906C2 (ru) | 2012-01-27 | 2019-09-02 | Вэриэйшн Биотекнолоджиз, Инк. | Способы и композиции для терапевтических агентов |
| EP2859011B1 (en) * | 2012-06-06 | 2019-12-11 | Bionor Immuno AS | Peptides derived from viral proteins for use as immunogens and dosage reactants |
| US10335482B2 (en) | 2012-06-06 | 2019-07-02 | Bionor Immuno As | Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
| EP3033106A1 (en) * | 2013-08-14 | 2016-06-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Immunoadjuvant compositions and uses thereof |
| EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
| EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| WO2015086738A2 (en) * | 2013-12-11 | 2015-06-18 | Bionor Immuno As | Hiv vaccine |
| AU2015208032B2 (en) | 2014-01-27 | 2020-07-30 | Bionor Immuno As | Dosage regimen for HIV vaccine |
| AU2015208033B2 (en) | 2014-01-27 | 2019-02-07 | Bionor Immuno As | Method for the vaccination against HIV |
| WO2015110659A1 (en) * | 2014-01-27 | 2015-07-30 | Bionor Immuno As | Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response |
| IL248059B2 (en) * | 2014-04-03 | 2023-10-01 | Amgen Inc | Method for preparing AMG 416 |
| WO2016005508A1 (en) | 2014-07-11 | 2016-01-14 | Bionor Immuno As | Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids) |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| JP2018515603A (ja) | 2015-05-04 | 2018-06-14 | ビオノル・イムノ・アクシェセルスカプＢｉｏｎｏｒ Ｉｍｍｕｎｏ ＡＳ | Ｈｉｖワクチン用の投薬レジメン |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62164696A (ja) | 1986-01-06 | 1987-07-21 | エフ．ホフマン ― ラ ロシュ アーゲー | ＨＴＬＶ−３ｇａｇ遺伝子の発現 |
| US4925784A (en) | 1986-04-04 | 1990-05-15 | Hoffmann-La Roche Inc. | Expression and purification of an HTLV-III gag/env gene protein |
| GB8629116D0 (en) | 1986-12-05 | 1987-01-14 | Hoffmann La Roche | Env/gag polypeptides |
| PT88416B (pt) | 1987-09-04 | 1992-10-30 | Wellcome Found | Processo para determinacao imunologica de anticorpos e processo para a preparacao de uma proteina com capacidade de ligacao a anticorpos e de composicoes farmaceuticas que a contem |
| US4888290A (en) * | 1987-11-06 | 1989-12-19 | Coulter Corporation | Monoclonal antibody specific to HIV antigens |
| EP0356007A3 (en) | 1988-07-22 | 1991-07-03 | Medical Research Council | Antigenic determinants |
| KR940000755B1 (ko) * | 1990-02-16 | 1994-01-29 | 유나이티드 바이오메디칼 인코오포레이티드 | Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드 |
| SE468168B (sv) | 1990-02-20 | 1992-11-16 | Replico Medical Ab | Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov |
| US5288514A (en) * | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| FR2703252B1 (fr) * | 1993-03-31 | 1996-09-06 | Fernand Narbey Torossian | Complexe immunomodulateur anti SIDA. |
| AU7101294A (en) * | 1993-06-07 | 1995-01-03 | Endocon, Inc. | Implant stimulated cellular immunity |
| CN1055701C (zh) * | 1993-10-19 | 2000-08-23 | 味之素株式会社 | 能诱导对hiv免疫应答的肽及含有该肽的预防、治疗aids的药物 |
| FR2731013B1 (fr) * | 1995-02-27 | 1997-05-16 | Inst Nat Sante Rech Med | Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications |
| WO1998040744A1 (de) * | 1997-03-10 | 1998-09-17 | Roche Diagnostics Gmbh | Verfahren zur simultanen bestimmung von hiv-antigenen und hiv-antikörpern |
-
1999
- 1999-03-04 NO NO19991078A patent/NO311807B1/no not_active IP Right Cessation
-
2000
- 2000-03-02 EA EA200100943A patent/EA004802B9/ru not_active IP Right Cessation
- 2000-03-02 ID IDW00200102137A patent/ID30497A/id unknown
- 2000-03-02 HU HU0200265A patent/HU229282B1/hu not_active IP Right Cessation
- 2000-03-02 NZ NZ525752A patent/NZ525752A/en not_active IP Right Cessation
- 2000-03-02 DE DE60039036T patent/DE60039036D1/de not_active Expired - Lifetime
- 2000-03-02 AU AU33358/00A patent/AU771827B2/en not_active Ceased
- 2000-03-02 NZ NZ525751A patent/NZ525751A/en not_active IP Right Cessation
- 2000-03-02 BR BR0008741-6A patent/BR0008741A/pt not_active IP Right Cessation
- 2000-03-02 CN CNA2008100921330A patent/CN101328208A/zh active Pending
- 2000-03-02 WO PCT/NO2000/000075 patent/WO2000052040A1/en active IP Right Grant
- 2000-03-02 PT PT00911492T patent/PT1159298E/pt unknown
- 2000-03-02 CN CNA2008100921311A patent/CN101328209A/zh active Pending
- 2000-03-02 CA CA002363947A patent/CA2363947C/en not_active Expired - Fee Related
- 2000-03-02 AT AT00911492T patent/ATE397014T1/de active
- 2000-03-02 CZ CZ20013195A patent/CZ300505B6/cs not_active IP Right Cessation
- 2000-03-02 SK SK1240-2001A patent/SK287382B6/sk not_active IP Right Cessation
- 2000-03-02 ES ES00911492T patent/ES2307496T4/es not_active Expired - Lifetime
- 2000-03-02 CN CNA2008100921326A patent/CN101328210A/zh active Pending
- 2000-03-02 CN CNB008057354A patent/CN100387617C/zh not_active Expired - Fee Related
- 2000-03-02 NZ NZ514619A patent/NZ514619A/en not_active IP Right Cessation
- 2000-03-02 DK DK00911492T patent/DK1159298T3/da active
- 2000-03-02 US US09/674,674 patent/US6706859B1/en not_active Expired - Lifetime
- 2000-03-02 NZ NZ525753A patent/NZ525753A/en not_active IP Right Cessation
- 2000-03-02 JP JP2000602264A patent/JP2002541069A/ja active Pending
- 2000-03-02 EP EP00911492A patent/EP1159298B1/en not_active Expired - Lifetime
-
2001
- 2001-08-27 ZA ZA200107072A patent/ZA200107072B/xx unknown
-
2002
- 2002-08-27 HK HK02106292.0A patent/HK1044778B/zh not_active IP Right Cessation
-
2003
- 2003-09-11 US US10/659,324 patent/US7311915B2/en not_active Expired - Fee Related
-
2007
- 2007-10-01 US US11/865,106 patent/US7709003B2/en not_active Expired - Fee Related
- 2007-10-01 US US11/865,109 patent/US7709004B2/en not_active Expired - Fee Related
-
2008
- 2008-08-28 CY CY20081100922T patent/CY1108299T1/el unknown
-
2010
- 2010-12-09 JP JP2010275025A patent/JP5313998B2/ja not_active Expired - Fee Related
-
2012
- 2012-10-31 JP JP2012239940A patent/JP5695010B2/ja not_active Expired - Fee Related
- 2012-10-31 JP JP2012240131A patent/JP5695012B2/ja not_active Expired - Fee Related
-
2013
- 2013-12-02 JP JP2013249096A patent/JP5814331B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO311807B1 (no) | HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV | |
| US7612168B2 (en) | Modified HIV peptides, antigens, compositions, immunoassay kit and a method of detecting antibodies induced by HIV | |
| AU2001282706A1 (en) | HIV peptides from conserved in gag p17 and 924 and their application in E.G. vaccines | |
| AU2004200155C1 (en) | HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |